Mirum Pharmaceuticals earnings trigger fresh focus on losses

Mirum Pharmaceuticals (MIRM) reported second quarter and first half 2026 results that showed much larger net losses than a year earlier. This is likely the key factor drawing investor attention this month.

Despite the latest earnings revealing much wider losses, Mirum Pharmaceuticals’ share price tells a different story, with a year to date share price return of 28.91% and a 1 year total shareholder return of 50.93%. Over a longer period, the 3 year total shareholder return of roughly 3x and a very large 5 year total shareholder return suggest that momentum has been building over several years rather than only in recent months.

If rising losses at Mirum have you thinking more broadly about high growth opportunities in healthcare, it can help to scan a wider field of 42 healthcare AI stocks.

Mirum Pharmaceuticals now trades at around US$100, yet the current share price still sits well below both analyst targets and some intrinsic value estimates. Is the fair value closer to those higher numbers or nearer to today’s level?

Most Popular Narrative: 30.2% Undervalued

Mirum Pharmaceuticals last closed at about $100.64, while the most followed valuation narrative puts fair value closer to $144.15. That gap hinges on a handful of assumptions about future growth and profitability.

The analysts have a consensus price target of $144.15 for Mirum Pharmaceuticals based on their expectations of its future earnings growth, profit margins and other risk factors.

However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $185.0, and the most bearish reporting a price target of $115.0.

Want to understand why this narrative sees Mirum Pharmaceuticals as so undervalued? The story leans heavily on expectations for rapid revenue expansion, a sharp profitability swing and a richer future earnings multiple. This raises the question of which specific growth path underpins that fair value and how much profit power is being implied.

Result: Fair Value of $144.15 (UNDERVALUED)

However, this Mirum Pharmaceuticals narrative can quickly change if Livmarli faces tougher reimbursement decisions, or if key late stage trials such as VISTAS disappoint.

Next Steps

With mixed signals around Mirum Pharmaceuticals, it makes sense to move quickly and look at the full picture for yourself. To weigh the balance of concerns and potential upsides, start with these 3 key rewards and 2 important warning signs.

Looking for more investment ideas beyond Mirum Pharmaceuticals?

If Mirum Pharmaceuticals has sharpened your appetite for opportunities, do not stop here. Broaden your watchlist now or risk missing what other investors could be spotting early.

• Explore the potential for upside by scanning screener containing 19 high quality undiscovered gems that combine strong fundamentals with relatively low market attention.
• Consider resilience by reviewing 80 resilient stocks with low risk scores that score well on financial strength and business stability.
• Focus on quality by assessing solid balance sheet and fundamentals stocks screener (50 results) featuring companies with healthier balance sheets and durable fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.